This trial is testing mepolizumab as a possible treatment for COPD. 800 people will be randomly assigned to either the treatment group or the placebo group. The treatment group will receive mepolizumab and the placebo group will not receive the treatment. The trial will last for up to 104 weeks.
1 Primary · 5 Secondary · Reporting Duration: Up to Week 104
800 Total Participants · 2 Treatment Groups
Primary Treatment: Mepolizumab · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||50.0%|
|GSK Investigational Site||100.0%|
|Did not meet criteria||37.5%|